Antiretoviral therapy and the lipodystrophy syndrome, part 2: Concepts in aetiopathogenesis

Antiviral Therapy

Volumn 6, Issue 3, 2001, Pages 145-160

  Nolan, D ^a   John, M ^a   Mallal, S ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; THYMIDINE DERIVATIVE; ZIDOVUDINE;

ADIPOCYTE; CELL MATURATION; CLINICAL RESEARCH; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIPODYSTROPHY; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS FAT; SUBCUTANEOUS FAT DISORDER;

ADIPOCYTES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV PROTEASE INHIBITORS; HUMANS; LIPODYSTROPHY; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0035666441     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Antiretroviral therapy and the lipodystrophy syndrome
2. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy
3. Lipopatrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients
4. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
5. Effect of ritonavir on lipids and post-heparin lipase in normal subjects
6. Metabolic effects of indinavir in healthy HIV-seronegative men
7. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of change in body composition in patients with HIV infection
8. Lipid profiles in HIV-infected patients before and after protease inhibitor therapy
9. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
10. Effects of protease inhibitors on hyperglyceamia, hyperlipidaemia, and lipodystrophy. A 5-year cohort study
11. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine cohort, France, 1996 to 1998
12. Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomised controlled studies of combination antiretroviral therapy
13. Assessment of lipodystrophy in patients previously exposed to AZT, ddI or ddC, but naïve for d4T and protease inhibitors (PI), and randomised between d4T/3TC/Indinavir and AZT/3TC/Indinavir (NOVAVIR trial)
14. Prevalence of lipodystrophy in long term follow up of a clinical trial comparing various combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI), ALBI trial: ANRS 070
15. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection
16. The effect of treatment intensification in HIV-infection: A study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine
17. Effect of NRTI intensification on prevalence of body composition abnormalities at week 144 of ritonavir plus saquinavir therapy in an HIV-infected cohort
18. Ritonavir and saquinavir combination therapy for the treatment of HIV infection
19. Lipodystrophy in protease-inhibitor-naive HIV-infected patients
20. Visceral abdominal-fat accumulation associated with use of indinavir
21. Risk of developing metabolic alterations in PI-naive HIV-1 infected patients treated with RTI
22. Stavudine use is not associated with an incremental risk of hyperlipidaemia during treatment with HIV-1 protease inhibitors
23. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy
24. Differences in postprandial lipid metabolism in patients with PI-associated and NRTI-associated lipodystrophy
25. Anti-oxidants rescue NRTI-induced metabolic changes in AKR/J mice
26. 3T3 fibroblasts transfected with a cDNA for mitochondrial aspartate aminotransferase express plasma membrane fatty acid-binding protein and saturable fatty acid uptake
27. Mitochondrial aspartate aminotransferase: Direction of a single protein with to distinct functions to two subcellular sites does not require alternative splicing of the mRNA
28. Characterization of the native and recombinant catalytic subunit of human DNA polymerase γ: Identification of residues critical for exonuclease activity and dideoxynucleotide sensitivity
29. Mitochondrial toxicity induced by nucleoside analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
30. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity
31. Mitochondrial toxicity and HIV therapy
32. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis
33. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals
34. Clinical pharmacokinetics of nucleoside anti-retroviral in agents
35. Comparison of metabolism and in vitro antiviral activity of stavudine versus other 2′-3′-dideoxynucleoside analogues
36. Human thymidine kinase 2: Molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates
37. A deoxyribonucleotidase in mitochondria: Involvement in regulation of dNTP pools and possible link to genetic disease
38. Structural basis for efficient phosphorylation of 3′-azidothymidine monophosphate by Escherichia coli thymidylate kinase
39. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues
40. Expression of human mitochondrial thymidine kinase in Escherichia coli: Correlation between the enzymatic activity of pyrimidine nucleoside analogues and their inhibitory effect on bacterial growth
41. Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line
42. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells
43. Cloning and expression of human deoxyguanosine kinase cDNA
44. Decrease of mitochondrial DNA content in adipose tissue of HIV-1-infected patients treated with NRTIs
45. Analysis of subcutaneous adipose tissue mitochondrial DNA from individuals with HAART-associated lipodystrophy
46. Mitochondrial DNA depletion, assessed by real-time PCR-based quantitative assay, in subcutaneous fat of HIV-infected patients: Evidence for a role in the etiology of fat wasting
47. Light and electron microscopy findings in subcutaneous fat in antiretroviral treated and HIV-infected patients
48. An ultrastructural insight into the pathogenesis study of HAART-associated partial lipodystrophy
49. Morphologic correlates of mitochondrial dysfunction in children
50. The universality of bioenergetic disease and amelioration with redox therapy
51. Effects of cellular ATP depletion on glucose transport and insulin signalling in 3T3-L1 adipocytes
52. Decreased fatty acid synthesis due to mitochondrial uncoupling in adipose tissue
53. AMP-activated protein kinase, a metabolic master switch: Possible roles in Type 2 diabetes
54. Malonyl-CoA, fuel sensing, and insulin resistance
55. The AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell?
56. Inhibition of lipolysis and lipogenesis in isolated rat adipocytes with AICAR, a cell-permeable activator of AMP-activated protein kinase
57. Mitochondrial proteins at unexpected locations: Export of proteins from mitochondria from an evolutionary perspective
58. Mitochondrial aspartate aminotransferase expressed on the surface of 3T3-L1 adipocytes mediates saturable fatty acid uptake
59. Regulation of adipocyte gene expression by polyunsaturated fatty acids
60. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein
61. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels
62. Lipodystrophy defined by a clinical score in HIV-infected men on highly active anti-retroviral therapy: Correlation between dyslipidaemia and steroid hormone alterations
63. Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART)
64. Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: Association with the development of lipodystrophy
65. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
66. Influence of protease inhibitor therapy on lipoprotein metabolism
67. Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors
68. HIV-associated fat redistribution is associated with marked acceleration of lipid turnover
69. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
70. The adipocyte, fatty acid trapping, and atherogenesis
71. The HIV-protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance
72. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes
73. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
74. Inhibition of adipocyte differentiation in HIV-1 protease inhibitors: Potential mechanisms based on changes in gene expression
75. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors
76. Inhibition of adipocyte differentiation by HIV protease inhibitors
77. Hyperlipoproteinaemia in HIV patients is linked to sterol-regulatory element-binding protein (SREBP)-1c
78. Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: Implications for adipocyte differentiation and metabolism
79. ADD-1 provides new insight into the mechanisms of insulin action
80. Sterol Regulatory Element-binding Proteins (SREBPs): Key regulators of nutritional homeostasis and insulin action
81. Molecular basis of partial lipodystrophy and prospects for therapy
82. Dialogue between muscle and fat
83. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver
84. The hormone resistin links obesity to diabetes
85. Depot-related gene expression in human subcutaneous and omental adipocytes
86. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation
87. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease
88. Characterization of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue
89. Preferential channeling of energy fuels toward fat rather than muscle during high free fatty acid availability in rats
90. The regulation of adipose tissue distribution in humans
91. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy
92. Hyperandrogenemia in human immunodeficiency virus-infected women with lipodystrophy syndrome
93. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
94. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis
95. HIV protease inhibitor therapy increases hepatic lipoprotein production via stabilisation of activated Sterol Regulatory Element-Binding Protein-1 (SREBP-1) in the nucleus
96. The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells
97. The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle
98. Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes
99. Physiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: An hypothesis
100. Getting to the HAART of insulin resistance
101. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increasea in the HIV lipodystrophy syndrome
102. Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy
103. Cellular targets of 3′-azido-3′-deoxythymidine: An early (non-delayed) effect on oxidative phosphorylation
104. Mitochondria as cell targets of AZT (zidovudine)
105. Zidovudine-induced experimental myopathy: Dual mechanism of mitochondrial damage
106. Predominant expression of the mitochondrial dicarboxylate carrier in white adipose tissue
107. Effects of gender and race in the antiretroviral therapy associated lipodystrophy syndrome
108. 3-adrenergic receptor polymorphism and the antiretroviral therapy-related lipodystrophy syndrome
109. TNF-α promoter region polymorphisms in patients with HIV-1 associated lipodystrophy
110. The role of TNFα and TNF receptors in obesity and insulin resistance